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Introduction: Researchers planning cluster-randomized controlled trials (cRCTs) require estimates of the
intra-cluster correlation coefﬁcient (ICC) from previous studies for sample size calculations. This paper
ﬁlls a persistent gap in the literature by providing estimates of ICCs for many key HIV-related clinical
outcomes.
Methods: Data from HIV-positive patients from 47 HIV care and treatment clinics in Dar es Salaam,
Tanzania were used to calculate ICCs by site of enrollment or site of ART initiation for various clinical
outcomes using cross-sectional and longitudinal data. ICCs were estimated using linear mixed models
where either clinic of enrollment or clinic of ART initiation served as the random effect.
Results: ICCs ranged from 0 to 0.0706 (95% CI: 0.0447, 0.1098). For most outcomes, the ICCs were large
enough to meaningfully affect sample size calculations. For binary outcomes, the ICCs for event preva-
lence at baseline tended to be larger than the ICCs for later cumulative incidences. For continuous
outcomes, the ICCs for baseline values tended to be larger than the ICCs for the change in values from
baseline.
Conclusion: The ICCs for HIV-related outcomes cannot be ignored when calculating sample sizes for
future cluster-randomized trials. The differences between ICCs calculated from baseline data alone and
ICCs calculated using longitudinal data demonstrate the importance of selecting an ICC that reﬂects a
study's intended design and duration for sample size calculations. While not generalizable to all contexts,
these estimates provide guidance for future researchers seeking to design adequately powered cRCTs in
Sub-Saharan African HIV treatment and care clinics.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., Care and treatment clinics;
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Inc. This is an open access article u1. Introduction
HIV treatment programs in sub-Saharan Africa currently
deliver antiretroviral treatment (ART) and pre-ART care to mil-
lions of patients [1]. However, the long-term success of HIV
treatment programs depends on identifying models of treatment
delivery that provide quality care at a low cost. For many of the
most important aspects of HIV treatment delivery, the smallest
unit which allows variation in delivery approaches is the treat-
ment facility. For instance, health systems integration, healthnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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characteristics of facilities that cannot be varied at the level of
individual patients. Many other factors, such monitoring and
screening approaches, which theoretically could be varied at the
level of the patient, will be impractical or impossible to vary
within a facility for managerial or political reasons. Because
treatment facility is often the smallest unit that allows for
randomization, cluster randomized controlled trials (cRCTs) have
become a methodological mainstay for HIV treatment imple-
mentation research, as evidenced by their use in trials investi-
gating testing and counseling [2], treatment as prevention [3,4],
provision of care by peer health workers [5,6] and tuberculosis
prevention [7].
Unlike traditional randomized trials, cRCTs randomize entire
pre-existing groups, such as health centers or neighborhoods, to
different study arms. cRCTs are advantageous when interventions
are naturally implemented at the group level, when denying some
group members access to the intervention would be challenging or
unacceptable, or to minimize contamination of study arms [8e10].
However, combining group-level randomization with individual-
level analysis creates challenges for study design. Because sub-
jects from the same cluster often share characteristics such as be-
liefs, behaviors, or environments, their outcomes are often
correlated. Consequently, each subject in a cRCT provides less in-
dependent information than a subject in a comparable individually
randomized trial. In the analysis phase, ignoring the correlation
between cluster members will increase the type-I error rate.
However, if the correlation between cluster members is accounted
for in the analysis phase but ignored during the design phase,
sample size calculations will underestimate the true number of
subjects required to adequately power the cRCT, increasing the
type-II error rate [11e13].
Researchers commonly adjust for this correlation bymultiplying
the sample size required for a comparable individually randomized
trial by the “Design Effect,” also known as the “Variance Inﬂation
Factor.” The Design Effect is a function of the number of individuals
per cluster, m, and the intra-cluster correlation coefﬁcient (ICC), a
parameter that describes the proportion of the total variation in
outcomes that is due to variation between clusters [9].
Design Effect ¼ 1þ ðm 1Þ*ICC
Typically, researchers designing cRCTs rely on previously pub-
lished ICCs for their sample size calculations. However, because
ICCs depend on a study's outcome, design, analytic plan, and
population, researchers often struggle to ﬁnd published ICCs that
apply to their study [14]. Despite calls for increased publications of
ICCs for a range of outcomes [15], fewer than 20% of both health-
related and HIV-related cRCTs report their ICCs [16,17].
Only three previous studies have attempted to ﬁll this gap by
reporting ICCs for a range of HIV-related outcomes. Of these
studies, two focused on sexual attitudes and behaviors among
adolescents and young adults in the United States [18,19]. One
study calculated ICCs for outcomes among people living with
HIV, but included only a limited number of clinical outcomes and
calculated ICCs using baseline data alone, which is applicable to
future cross-sectional studies but not necessarily prospective
studies [20]. This paper aims to provide estimates of the ICC for
HIV-related clinical outcomes calculated both cross-sectionally
and longitudinally among clinics supporting patients enrolled
in a large urban HIV care and treatment program in Dar es
Salaam, Tanzania.2. Methods
2.1. Study population
Data were obtained from an ongoing cohort of HIV-infected
adult patients (>15 years old) from 47 HIV care and treatment
clinics (CTCs) in Dar es Salaam, Tanzania [21]. These clinics are
supported by the local NGO, Management and Development for
Health (MDH), with additional support from the President's
Emergency Plan for AIDS Relief (PEPFAR) and a longstanding
collaborative relationship with the Harvard T.H. Chan School of
Public Health. All adult patients with data on their site of enroll-
ment or site at the time of ART initiation who were enrolled be-
tween October 2004 and September 2012 were eligible for
inclusion in the study. Only ART-initiated patients were considered
when calculating ICCs for ART non-adherence, immunologic failure
endpoints, elevated alanine transaminase (ALT) levels, and weight
loss after ART initiation. Pregnant women were excluded when
calculating ICCs for anemia, weight-related outcomes, and plasma
lipid level outcomes. Patients who received tuberculosis treatment,
had severe anemia, or were overweight or obese at enrollment, as
well as patients who had elevated ALT levels at ART initiation were
excluded when calculating cumulative incidences for these out-
comes. The study was approved by institutional review boards for
human research at the Muhimbili University of Health and Allied
Sciences and the Harvard T.H. Chan School of Public Health.2.2. Data collection
Outcomes included in this paper had been previously studied in
this cohort, and data collection methods are described in detail
elsewhere [21e28]. Brieﬂy, patients received treatment according
to Tanzanian National and World Health Organization guidelines
[29,30]. ART-eligible patients returned for monthly visits while
ART-ineligible patients returned for care and monitoring visits
every 4 months. A comprehensive patient tracking system ensured
that patients could be encouraged to return to the clinic as nee-
ded.At each visit, health care providers completed standardized
forms including demographic, clinical, laboratory, and therapeutic
information. Data reviewers at each clinic ensured that data
recorded by healthcare workers were accurate and complete, and
professional data entry clerks entered these data into a secure
computerized database daily. A data management team performed
weekly quality assurance checks.2.3. Study variables
Data on deaths were obtained through notiﬁcation by family,
friends, or community-based patient tracking teams. If the death
date was unknown but the patient was known to have died, the
date of the last clinical visit was used as the death date. Loss to
follow up was deﬁned as having no clinic visits for >6 months from
the date of ﬁle closing among patients not initiated on ART or as
having no clinic visits or ART reﬁlls for >3 months from the date of
ﬁle closing among ART-initiated patients. Any patients prescribed
anti-tuberculosis medications within the ﬁrst 30 days of enroll-
ment were considered to have prevalent tuberculosis at enroll-
ment. Incident tuberculosis was deﬁned as having been prescribed
anti-tuberculosis medications during follow-up among patients
who were not diagnosed with tuberculosis within 30 days of
enrollment. Severe anemia was deﬁned as hemoglobin levels
<8.5 g/dL. Underweight was deﬁned as having a BMI<18.5,
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[31]. Abnormal lipid levels included high triglycerides
(TG  150 mg/dL), high total cholesterol (TC  200 mg/dL), high
low-density lipoprotein cholesterol (LDL-c130 mg/dL), low high-
density lipoprotein cholesterol (HDL-c<40 mg/dL), and dyslipide-
mia (TG  150 mg/dL, TC  200 mg/dL, LDL-c130 mg/dL, or HDL-
c<40 mg/dL) [31]. When calculating ICCs for continuous variables
and for lipid level-related outcomes, the timewindows used for the
baseline, 6, 12, and 24-month measurements were 0e2, 3e8, 9e17,
and 18e29 months, respectively.
Patients became eligible for immunologic failure 168 days after
ART initiation, at which point immunologic failure was evaluated
according to 5 alternative deﬁnitions: (a) CD4þ count <100, (b)
50% drop in CD4þ count from its peak value, (c) a return to pre-
ART CD4þ count or lower, (d) failure by Tanzanian criteria,
deﬁned as either a 50% drop in CD4þ count from its peak value or
a return to pre-ART CD4þcount or lower, or (e) by any of the above
criteria [29,30]. Eligibility for second-line ART was deﬁned as
either a 50% drop in CD4þ count from its peak value and a return
to pre-ART CD4þ count after 168 days on ART or a viral load
greater than 10,000 after 168 days on ART. Hepatotoxicity was
deﬁned as ALT>40 IU/L and ALT>120 IU/L. Signiﬁcant weight loss
after ART initiation was deﬁned as weight loss 5% of the weight
recorded at ART initiation. Because 95% adherence to ART or better
is required for optimal viral suppression [32], non-adherence was
said to have occurred when the number of days late to an
appointment or ART pick-up was 5% or more of the total days
between scheduled appointments or ART pick-ups.
2.4. Statistical methods
To reﬂect the unadjusted, intent-to-treat analysis that would
typically be used for most cRCTs, we calculated unadjusted ICCs
using linear mixed models with the patients' site of enrollment as
the random effect for outcomes calculated among all patients and
site of ART initiation as the random effect for outcomes calculated
only among ART-initiated patients:
Yij ¼ b0 þ bi þ eij;
where-
varðbiÞ ¼ s2B; var

eij
 ¼ s2W ; cov bi ; eij ¼ 0; EðbiÞ ¼ Eeij ¼ 0; Yij
is the measured outcome for patient j from site i, s2B is the between-
clinics variance, and eij is the within-clinic variance. The ICC was
calculated as:
dICC ¼ cs2Bcs2B þds2W
Lower and upper limits of the 95% conﬁdence intervals were
estimated as described in Hankinson et al. [33]: dICC1±1:96 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃdvarIcCC1r 1!
where
dvardICC1y 1bs2Bdvar
bs2Wþ
bs2W2bs2B4 dvar
bs2b
 2
bs2W2bs2B3 dcov
bs2w; bs2bTo ensure stability of the ICCs, sites with fewer than 5 events for
binary outcomes or fewer than 10 measurements for continuous
outcomes were excluded from the ICC calculation. Sites were also
excluded from the ICC calculation if they were extreme outliers,
deﬁned as having a site-speciﬁc outcome greater than 3 inter-
quartile ranges (IQRs) below the 25th percentile or above the 75th
percentile. These exclusion criteria were selected to improve the
stability of the estimates for the ICCs. However, because researchers
designing their own cRCTs would typically select appropriately
sized clusters containing more than 10 continuous observations or
5 binary events, using the current exclusion criteria may also
reasonably reﬂect the conditions of a real cRCT. Due to these
exclusion criteria, although a total of 47 sites are included in the
MDH database, the number of sites used in the calculation of the
ICCs ranged from 7 to 44, with median of 26. Analyses were
calculated using SAS, Release 9.2 (SAS Institute, Cary, NC, USA). ICCs
and their conﬁdence intervals were calculated with a publically
available SAS macro available on the last author's website [34].
3. Results
Of the 109,943 patients enrolled in MDH since 2004, 109,320
had information on their site of enrollment and 73,862 of the
74,067 patients who were initiated on ART over follow-up had in-
formation on their site of ART initiation. Table 1 presents the dis-
tribution of patients and patient visits by site of enrollment and
ART initiation. A detailed description of the baseline sociodemo-
graphic and clinical characteristics of the study population has been
discussed elsewhere [26,27]. Over the ﬁrst 2 years of follow up, only
4.6% of total patient-visits occurred at a site that was different from
the patients' original site of enrollment. Among those patients who
were initiated on ART, only 8.4% of patient-visits occurring between
the date of ART initiation and the date two years after the patient
ﬁrst became eligible for immunologic failure or second line-drugs
took place at a site that was different from the patients' original
site of ART initiation.
Table 2 presents descriptive statistics and ICCs for general health
outcomes among all patient. The ICCs in Table 2 ranged from 0.0050
(95% CI: 0.0022, 0.0110) for receiving tuberculosis treatment and
0.0544 (0.0343, 0.0850). Table 3 presents descriptive statistics and
ICCs for nutritional outcomes among all non-pregnant patients. The
ICCs for nutritional outcomes ranged more widely than for the
general health outcomes spanning from 0.0641, (95% CI: 0.0366,
0.1100) for overweight at baseline to 0.0009, (95% CI: 0.0003,
0.0030) for the 6-month cumulative incidence for obesity. For both
general health outcomes and nutritional outcomes, ICCs for a given
outcome tended to be higher at enrollment than for subsequent
visits. However, among subsequent visits, the ICCs tended to in-
crease with time since enrollment.
Table 4 presents descriptive statistics and ICCs for plasma lipid
level outcomes among patents. Because fewer individuals provided
data on plasma lipid level measurements, fewer sites met the
criteria for inclusion in the estimation of the ICCs, and the conﬁ-
dence intervals for lipid level ICCs tended to be relatively large. In
some cases, the conﬁdence intervals for the ICCs could not be
estimated; however, the point estimates of these ICCs were inves-
tigated and judged to be reasonable given site-speciﬁc data. The
ICCs for lipid level outcomes tended to be smaller than the ICCs
reported in Table 2, ranging from 0.0207 (95% CI: 0.0067, 0.0622)
for prevalence of low HDL at enrollment to 0 for the prevalence of
high total cholesterol at 24 months, cumulative incidence of high
LDL levels at 12 and 24 months, and change in ALT from baseline to
12 months. As in Table 2, the point estimate for the ICC of an
outcome at enrollment tended to be higher than the ICC for that
outcome over follow-up.
Table 1
Distribution of patients and patient visits by Care and Treatment Clinic (CTC) of among patients enrolled between 1 October 2004 and 30 September 2012 (K ¼ 47).
CTC Patients N (%) Patient-visits N (%) ART Patients N (%) ART Patient-Visits N (%)
1 78 (0.1%) 334 (0.01%) 67 (0.1%) 277 (0.02%)
2 3224 (3%) 64,984 (3%) 2060 (3%) 65,943 (4%)
3 16,550 (15%) 383,809 (17%) 11,428 (15%) 307,166 (17%)
4 25 (0.02%) 118 (0.01%) 23 (0.03%) 93 (0.01%)
5 83 (0.1%) 288 (0.01%) 64 (0.1%) 196 (0.01%)
6 7655 (7%) 151,134 (7%) 5307 (7%) 109,195 (6%)
7 143 (0.1%) 515 (0.02%) 80 (0.1%) 257 (0.01%)
8 1016 (1%) 13,601 (1%) 757 (1%) 13,228 (1%)
9 994 (1%) 9643 (0.4%) 804 (1%) 8219 (0.5%)
10 9193 (8%) 303,903 (13%) 7063 (10%) 242,948 (14%)
11 41 (0.04%) 173 (0.01%) 29 (0.04%) 129 (0.01%)
12 163 (0.1%) 792 (0.03%) 109 (0.1%) 560 (0.03%)
13 78 (0.1%) 4425 (0.2%) 297 (0.4%) 13,599 (1%)
14 1536 (1%) 22,541 (1%) 1003 (1%) 21,354 (1%)
15 904 (1%) 16,584 (1%) 586 (1%) 20,562 (1%)
16 81 (0.1%) 301 (0.01%) 68 (0.1%) 235 (0.01%)
17 278 (0.3%) 3070 (0.1%) 158 (0.2%) 2769 (0.2%)
18 181 (0.2%) 1925 (0.1%) 446 (1%) 15,390 (1%)
19 12 (0.01%) 20 (0.001%) 2 (0.003%) 2 (0.0001%)
20 63 (0.1%) 286 (0.01%) 51 (0.1%) 220 (0.01%)
21 10,257 (9%) 201,851 (9%) 7054 (10%) 132,293 (8%)
22 185 (0.2%) 10,402 (0.5%) 511 (1%) 27,529 (2%)
23 308 (0.3%) 3401 (0.1%) 165 (0.2%) 2553 (0.1%)
24 294 (0.3%) 7929 (0.3%) 533 (1%) 21,657 (1%)
25 509 (0.5%) 13,556 (1%) 505 (1%) 23,576 (1%)
26 240 (0.2%) 2399 (0.1%) 56 (0.1%) 555 (0.03%)
27 18,917 (17%) 350,279 (15%) 11,930 (16%) 237,488 (14%)
28 233 (0.2%) 987 (0.04%) 146 (0.2%) 610 (0.03%)
29 11 (0.01%) 38 (0.002%) 9 (0.01%) 29 (0.002%)
30 130 (0.1%) 513 (0.02%) 104 (0.1%) 404 (0.02%)
31 157 (0.1%) 1813 (0.1%) 127 (0.2%) 1986 (0.1%)
32 10,184 (9%) 210,227 (9%) 6145 (8%) 115,198 (7%)
33 2247 (2%) 41,575 (2%) 1539 (2%) 33,912 (2%)
34 83 (0.1%) 1857 (0.1%) 324 (0.4%) 17,523 (1%)
35 3792 (3%) 57,410 (3%) 2710 (4%) 39,141 (2%)
36 21 (0.02%) 92 (0.004%) 19 (0.03%) 90 (0.01%)
37 17,001 (16%) 381,128 (17%) 10,147 (14%) 258,708 (15%)
38 57 (0.1%) 179 (0.01%) 55 (0.1%) 181 (0.01%)
39 12 (0.01%) 44 (0.002%) 6 (0.01%) 23 (0.001%)
40 94 (0.1%) 332 (0.01%) 56 (0.1%) 219 (0.01%)
41 30 (0.03%) 153 (0.01%) 26 (0.04%) 127 (0.01%)
42 73 (0.1%) 315 (0.01%) 39 (0.1%) 211 (0.01%)
43 85 (0.1%) 410 (0.02%) 38 (0.1%) 163 (0.01%)
44 658 (1%) 9268 (0.4%) 417 (1%) 5238 (0.3%)
45 610 (1%) 10,596 (0.5%) 471 (1%) 9692 (1%)
46 103 (0.1%) 637 (0.03%) 64 (0.1%) 974 (0.1%)
47 731 (1%) 10,298 (0.4%) 264 (0.4%) 5980 (0.3%)
TOTAL 109,320 229,6135 73,862 1,758,402
Table 2
Intra-cluster correlations (ICCs) for general health outcomes, by site of MDH enrollment.
Outcome % or mean (SD) n/N or N Sites ICC (95% CI)
All cause Mortality
6 mo cumulative incidence 8% 8873/106,973 28 0.0084 (0.0045, 0.0155)
12 mo cumulative incidence 10% 10,261/106,973 28 0.0096 (0.0053, 0.0175)
24 mo cumulative incidence 11% 11,746/108,117 30 0.0128 (0.0074, 0.0223)
Loss to Follow-Up
6 mo cumulative incidence 3% 2730/105,495 21 0.0023 (0.0009, 0.0060)
12 mo cumulative incidence 17% 18,210/108,416 34 0.0123 (0.0067, 0.0223)
24 mo cumulative incidence 26% 28,062/108,416 34 0.0256 (0.0151, 0.0432)
CD4þ Count
Value at enrollment 266 (247) 87,229 44 0.0544 (0.0343, 0.0850)
Change from enrollment to 6 mo. 74 (202) 46,473 29 0.0022 (0.0007, 0.0065)
Change from enrollment to 12 mo. 98 (222) 42,930 27 0.0122 (0.0048, 0.0309)
Change from enrollment to 24 mo. 135 (247) 35,639 27 0.0486 (0.0266, 0.0873)
Receiving Tuberculosis Treatment
Prevalence at enrollment 10% 10,166/99,430 32 0.0297 (0.0176, 0.0495)
6 mo cumulative incidencea 6% 4996/87,219 29 0.0050 (0.0022, 0.0110)
12 mo cumulative incidencea 7% 6000/88,261 29 0.0076 (0.0035, 0.0163)
24 mo cumulative incidencea 8% 6955/88,996 30 0.0093 (0.0045, 0.0193)
a Excludes prevalent cases at baseline.
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Table 3
Intra-cluster correlations (ICCs) for nutritional outcomes by site of MDH enrollment among non-pregnant patients.
Outcome % or mean (SD) n/N or N Sites ICC (95% CI)
Severe anemia (hemoglobin<8.5 g/dL)
Prevalence at enrollment 20% 11,936/60,652 31 0.0048 (0.0024, 0.0098)
6 mo cumulative incidencea 10% 5827/57,144 24 0.0060 (0.0021, 0.0169)
12 mo cumulative incidencea 11% 7073/61,885 25 0.0082 (0.0033, 0.0198)
24 mo cumulative incidencea 13% 8376/65,127 26 0.0094 (0.0043, 0.0204)
Hemoglobin (g/dL)
Value at enrollment 10 (2) 65,619 43 0.0181 (0.0085, 0.0383)
Change from enrollment to 6 mo. 1 (2) 28,736 28 0.0074 (0.0026, 0.0205)
Change from enrollment to 12 mo. 1 (2) 25,782 27 0.0250 (0.0119, 0.0518)
Change from enrollment to 24 mo. 1 (3) 21,241 26 0.0258 (0.0123, 0.0533)
Underweight (BMI<18.5)
Prevalence at enrollment 25% 20,897/84,601 29 0.0281 (0.0159, 0.0492)
6 mo cumulative incidencea 11% 6916/63,658 22 0.0059 (0.0027, 0.0130)
12 mo cumulative incidencea 14% 8968/66,069 25 0.0067 (0.0032, 0.0141)
24 mo cumulative incidencea 16% 10,983/66,818 25 0.0066 (0.0031, 0.0136)
Overweight (BMI≥25)
Prevalence at enrollment 22% 18,516/84,631 30 0.0641 (0.0366, 0.1100)
6 mo cumulative incidencea 10% 7244/69,500 26 0.0022 (0.0007, 0.0072)
12 mo cumulative incidencea 17% 12,013/71,533 28 0.0112 (0.0076, 0.0263)
24 mo cumulative incidencea 23% 16,553/72,489 29 0.0259 (0.0131, 0.0506)
Obesity (BMI≥30)
Prevalence at enrollment 6% 5360/84,390 26 0.0130 (0.0065, 0.0258)
6 mo cumulative incidencea 3% 2609/82,013 23 0.0009 (0.0003, 0.0030)
12 mo cumulative incidencea 5% 4523/84,757 25 0.0013 (0.0005, 0.0036)
24 mo cumulative incidencea 8% 7006/85,716 25 0.0029 (0.0011, 0.0072)
BMI
Value at enrollment 22 (5) 83,594 31 0.0528 (0.0287, 0.0950)
Change from enrollment to 6 mo. 1 (3) 57,564 31 0.0122 (0.0056, 0.0265)
Change from enrollment to 12 mo. 2 (4) 48,218 27 0.0234 (0.0114, 0.0475)
Change from enrollment to 24 mo. 2 (4) 49,302 27 0.0159 (0.0068, 0.0031)
a Excludes prevalent cases at baseline.
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deﬁnitions of immunologic failure among ART initiated patients.
Cumulative incidences for immunologic failure were calculated
starting from the ﬁrst date of eligibility for immunologic failure,
which occurs 168 days after ART initiation. Despite having similar
clinical signiﬁcance, the ﬁve deﬁnitions of immunological failure
had relatively variable point estimates for the ICC, although their
conﬁdence intervals often overlapped substantially. The ICCs for
the cumulative incidence of immunologic failure by two of the
three single-item deﬁnitions, CD4þ cell count <100 and 50% drop in
CD4þ count from peak value, decreased over time. In contrast, the
ICCs for the cumulative incidence of immunologic failure deﬁned as
a return to pre-ART baseline CD4þ count or lower increased over
time. Immunologic failure by the Tanzanian criteria and by any
criteria, both of which are composite outcomes including at least
one deﬁnition of immunologic failure for which ICCs increased over
time as well as the deﬁnition of immunologic failure for which ICCs
decreased over time, did not show a monotonic trend.
Table 6 presents descriptive statistics and ICCs for additional
clinical outcomes among ART-initiated patients. ICCs ranged from
0.0707 (95% CI: 0.0448, 0.1099) for the 24-month cumulative inci-
dence of non-adherence to 0 for the change in ALT IU/L 12 months
from ALT initiation. As seen previously, ICCs for a given outcome
tended to increasewith time of ART initiation. However, ALT>40 IU/
L and ALT>120 IU/L, the only outcomes in Table 6 for which prev-
alence at ART initiationwas available, had lower ICCs for prevalence
at ART initiation than for cumulative incidences over follow-up.4. Discussion
This paper reports ICCs for key clinical outcomes among a large
cohort of HIV-positive adults. This cohort allowed for the calcula-
tion of ICCs for many novel outcomes. Furthermore, while previouspapers reporting ICCs for HIV-related outcomes relied exclusively
on data available at baseline [18e20], this paper estimated ICCs
using both cross-sectional and longitudinal data. Because most
cRCTs focus on longitudinal outcomes, these ICCs may better reﬂect
future researchers' chosen study designs than ICCs calculated from
baseline data alone.
For many binary outcomes, the ICC for prevalence at baseline
was larger than the ICCs calculated using longitudinal data. There
are three explanations for this pattern. First, the ICC for a binary
outcome is dependent on the probability of that outcome [35]. All
else being equal, we would expect the ICCs for prevalence at
baseline to be greater than the ICCs for cumulative incidences
whenever baseline prevalence was greater than later cumulative
incidences, as was the case formany outcomes in our study. Second,
when calculating the ICCs for incident outcomes, we excluded
prevalent cases. Afterwards, the remaining population of at-risk
patients at each clinic became more similar to each other than
the initial populations at each clinic had been, reducing both
between-clinic variation and the ICC. Third, it has been noted that
modeling time when calculating the ICC tends to meaningfully
reduce ICC estimates [14]. While time was not explicitly in our
calculations, several of our outcomes, such as the cumulative in-
cidences and changes from baseline values, investigated changes in
patients' status from baseline. By looking at changes in patients'
status over time, we were able to incorporate time into the deﬁ-
nition of our outcome. This implicit modeling of time may also help
explain why the ICCs for prevalence tended to be higher than ICCs
for cumulative incidence and why the ICCs for baseline values
tended to be higher than the ICCs for changes from baseline over
time. Regardless of the precise mechanisms, the differences be-
tween ICCs calculated using baseline data and ICCs calculated using
longitudinal data were often large enough to have substantial im-
plications for sample size calculations, highlighting the importance
Table 4
Intra-cluster correlations (ICCs) for plasma lipid levels by site of MDH enrollment.
Outcome % or mean (SD) n/N or N Sites ICC (95% CI)
Dyslipidemiaa
Prevalence at Enrollment 45% 17,093/38,046 26 0.0152 (0.0069, 0.0330)
Prevalence at 6 mo. 44% 3654/8290 21 0.0057 (0.0018, 0.0181)
Prevalence at 12 mo. 43% 3066/7074 16 0.0091 (0.0032, 0.0254)
Prevalence at 24 mo. 47% 2468/5215 17 0.0141 (0.0056, 0.0353)
Triglycerides (mg/dL)
Value at enrollment 134 (86) 36,504 26 0.0107 (0.0044, 0.0257)
Change from enrollment to 6 mo. 10 (90) 4801 15 0.0025 (0.0004, 0.0141)
Change from enrollment to 12 mo. 8 (96) 3916 11 0.0022 (0.0003, 0.0169)
Change from enrollment to 24 mo. 3 (104) 2868 13 0.0047 (0.0011, 0.0196)
High Triglycerides (>150 mg/dL)
Prevalence at Enrollment 30% 10,796/36,476 24 0.0072 (0.0030, 0.0174)
Prevalence at 6 mo. 20% 1622/7945 16 0.0049 (0.0015, 0.0159)
Prevalence at 12 mo. 20% 1375/6754 12 0.0083 (0.0028, 0.0241)
Prevalence at 24 mo. 24% 1182/4982 14 0.0131 (0.0045, 0.0375)
Total Cholesterol (mg/dL)
Value at enrollment 150 (63) 37,436 26 0.0070 (0.0027, 0.0180)
Change from enrollment to 6 mo. 14 (70) 4980 15 0.0066 (0.0022, 0.0201)
Change from enrollment to 12 mo. 19 (70) 4090 11 0.0099 (0.0029, 0.0334)
Change from enrollment to 24 mo. 17 (71) 3034 13 0.0151 (0.0048, 0.0467)
High Total Cholesterol (>200 mg/dL)
Prevalence at Enrollment 15% 5554/37,324 21 0.0039 (0.0012, 0.0126)
Prevalence at 6 mo. 19% 1552/8063 14 0.0007 (0.0001, 0.0081)
Prevalence at 12 mo. 22% 1537/6997 15 0.0011 (0.0001, 0.0107)
Prevalence at 24 mo. 25% 1273/5136 14 0
LDL (mg/dL)
Value at enrollment 88 (44) 8999 20 0.0147 (0.0057, 0.0371)
Change from enrollment to 6 mo. 1 (34) 1409 9 0.0121 (0.0031, 0.0455)
Change from enrollment to 12 mo. 4 (35) 949 8 0.0046 (0.0002, 0.0800)
Change from enrollment to 24 mo. 3 (51) 567 7 0.0173 (0.0016, 0.1649)
High LDL (>130 mg/dL)
Prevalence at Enrollment 11% 1014/8802 11 0.0075 (0.0026, 0.0220)
Prevalence at 6 mo. 13% 500/3767 9 0.0025 (0.0004, 0.0138)
Prevalence at 12 mo. 15% 537/3638 10 0
Prevalence at 24 mo. 16% 430/2636 10 0
HDL (mg/dL)
Value at enrollment 36 (18) 9061 20 0.0161 (0.0058, 0.0439)
Change from enrollment to 6 mo. 14 (20) 1463 9 0.0029 (0.0003, 0.0296)
Change from enrollment to 12 mo. 17 (20) 1020 8 0.0121 (0.0022, 0.0647)
Change from enrollment to 24 mo. 12 (28) 589 7 0.0066 (0.0003, 0.1438)
Low HDL (<40 mg/dL)
Prevalence at Enrollment 64% 5804/9069 21 0.0207 (0.0067, 0.0622)
Prevalence at 6 mo. 34% 1367/3963 13 0.0041 (0.0010, 0.0168)
Prevalence at 12 mo. 26% 975/3711 9 0.0043 (0.0010, 0.0188)
Prevalence at 24 mo. 29% 775/2696 10 0.0072 (0.0019, 0.0273)
a TG  150 mg/dL, or TC  200 mg/dL, or LDL-c130 mg/dL, or HDL-c<40 mg/dL.
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study designs rather than ICCs calculated using baseline data alone.
The ICCs for the different deﬁnitions of cumulative incidence of
immunologic failure did not demonstrate a consistent trend over
time. While ICCs for the cumulative incidence of immunologic
failure by the deﬁnitions of CD4þ cell count <100 and 50% drop in
CD4þ count from peak value increased over time, the ICCs for the
cumulative incidence of immunologic failure deﬁned as a return to
pre-ART baseline CD4þ count or lower decreased over time. While
it is unclear why the trend for ICCs over time should be different for
immunologic failure deﬁned as a return to pre-ART baseline CD4þ
count or lower than for most other outcomes included in this paper,
the high 6-month cumulative incidence of return to pre-ART
baseline CD4þ count or lower relative to the other single-item
deﬁnitions of immunologic failure may play a role. For the immu-
nologic failure deﬁned by either Tanzanian criteria or by any
criteria, the lack of a monotonic increasing trend in ICCs over time
may reﬂect the fact that both outcomes include a return to pre-ART
baseline CD4þ count or lower in their composite deﬁnition of
immunologic failure. The largest ICC observed in our study was for
the 24-month cumulative incidence of non-adherence. This ﬁndingis consistent with previous observations that behavioral outcomes
tend to have higher ICCs than physiologic outcomes. Our results are
also similar to previously published estimates from Zhang et al.
[20], who estimated ICCs from HIV clinics in Kenya, Namibia, and
Tanzania. Their unadjusted estimates for ICCs for any missed
medication does in the past 30 days as reported verbally
(ICC ¼ 0.029, 95% CI: 0.014, 0.069) and using a visual analog scale,
(ICC ¼ 0.041, 95% CI: 0.021, 0.095) overlap with our ICCs for ART
non-adherence. Their conﬁdence intervals for the ICC for CD4þ
count <200 (ICC¼ 0.019, 95% CI: 0.009, 0.048) also overlappedwith
our conﬁdence intervals of the ICC for CD4þ cell count <100. While
their unadjusted ICC for CD4þ count (ICC ¼ 0.017, 95% CI: 0.007,
0.043) was somewhat lower than our ICC for CD4þ count at base-
line, the conﬁdence intervals overlapped with our ICCs for change
in CD4þ count 6, 12, and 24 months from enrollment.
Over the time periods included in our analysis, only 4.6% of
patient-visits occurred at sites other than the site of enrollment
among the general population of MDH adult patients, and only 8.4%
of patient-visits occurred at sites other than the site of ART initia-
tion among patients who initiated ART. Because this variation in
visit site could inﬂuence the ICCs, we removed visits that occurred
Table 5
Intra-cluster correlations for immunologic failure outcomes (ICCs) by site of ART-initiation among patients initiated on ART.
Outcome % n/N Sites ICC (95% CI)
CD4þ cell count<100
6 mo cumulative incidencea 11% 3820/35,497 25 0.0088 (0.0043, 0.0180)
12 mo cumulative incidencea 14% 5471/33,539 25 0.0087 (0.0043, 0.0176)
24 mo cumulative incidencea 17% 6964/39,927 26 0.0106 (0.0056, 0.0201)
50% drop in CD4þ count from peak value
6 mo cumulative incidencea 11% 3781/35,353 24 0.0033 (0.0013, 0.0085)
12 mo cumulative incidencea 18% 7060/39,091 28 0.0086 (0.0039, 0.0189)
24 mo cumulative incidencea 27% 10,909/39,967 28 0.0253 (0.0131, 0.0481)
Return to pre-ART baseline CD4þ count or lower
6 mo cumulative incidencea 23% 7554/33,223 25 0.0206 (0.0105, 0.0403)
12 mo cumulative incidencea 30% 11,083/36,426 27 0.0117 (0.0057, 0.0240)
24 mo cumulative incidencea 37% 13,638/37,201 27 0.0095 (0.0045, 0.0197)
Immunologic failure by Tanzanian Criteriab
6 mo cumulative incidencea 25% 8897/35,535 26 0.0137 (0.0067, 0.0275)
12 mo cumulative incidencea 34% 13,445/39,091 28 0.0075 (0.0034, 0.0162)
24 mo cumulative incidencea 43% 17,355/39,967 28 0.0123 (0.0061, 0.0246)
Immunologic failure by any criteriac
6 mo cumulative incidencea 29% 10,230/35,568 28 0.0186 (0.0093, 0.0370)
12 mo cumulative incidencea 38% 14,744/39,100 29 0.0096 (0.0045, 0.0204)
24 mo cumulative incidencea 46% 18,489/39,976 29 0.0102 (0.0050, 0.0207)
a Cumulative incidences are calculated from the date of eligibility for immunologic failure which occurs 168 days after ART initiation.
b 50% drop in CD4þ count from peak value, or return to pre-ART baseline CD4þ count or lower after 6 months on ART.
c CD4þ Count <100, 50% drop in CD4þ count from peak value or return to pre-ART baseline CD4þ count or lower after 6 months on ART.
Table 6
Intra-cluster correlations (ICCs) by site of ART-initiation among patients initiated on ART.
Outcome % n/N Sites ICC (95% CI)
Non-Adherencea
6 mo cumulative incidence 59% 43,389/73,228 43 0.0161 (0.0090, 0.0286)
12 mo cumulative incidence 69% 50,911/73,268 44 0.0374 (0.0223, 0.0622)
24 mo cumulative incidence 75% 55,183/73,272 44 0.0707 (0.0448, 0.1099)
Eligibility for 2ND Line ARTb
6 mo cumulative incidencec 5.9% 2692/46,012 23 0.0027 (0.0011, 0.0065)
12 mo cumulative incidencec 11% 5076/47,381 25 0.0084 (0.0042, 0.0168)
24 mo cumulative incidencec 16% 7619/48,346 27 0.0225 (0.0124, 0.0405)
Hepatotoxicity
ALT>40 IU/L
Prevalence at ART initiation 14% 5675/41,909 26 0.0038 (0.0014, 0.0101)
6 mo cumulative incidenced 21% 7683/37,094 26 0.0129 (0.0064, 0.0259)
12 mo cumulative incidenced 25% 9870/40,163 28 0.0230 (0.0123, 0.0426)
24 mo cumulative incidenced 28% 11,694/41,293 28 0.0385 (0.0216, 0.0678)
ALT>120 IU/L
Prevalence at ART initiation 0.8% 278/36,791 9 0.0004 (0.0001, 0.0023)
6 mo cumulative incidenced 3% 1049/40,080 19 0.0011 (0.0004, 0.0031)
12 mo cumulative incidenced 3% 1290/43,359 20 0.0014 (0.0005, 0.0038)
24 mo cumulative incidenced 3% 1504/44,854 21 0.0020 (0.0007, 0.0056)
ALT (IU/L)
Value at enrollment 29 (29) 36,663 32 0.0047 (0.0022, 0.0102)
Change from initiation to 6 mo. 2 (54) 22,236 23 0.0002 (0.0000, 0.0021)
Change from initiation to 12 mo. 3 (64) 19,599 26 0
Change from initiation to 24 mo. 4 (34) 16,408 24 0.0008 (0.0002, 0.0034)
Weight Loss >5% after ART initiatione
6 mo cumulative incidence 23% 16,039/70,180 38 0.0079 (0.0039, 0.0159)
12 mo cumulative incidence 28% 19,887/70,436 38 0.0154 (0.0081, 0.0291)
24 mo cumulative incidence 33% 23,357/70,465 38 0.0297 (0.0169, 0.0514)
a The number of days late to an appointment or an ART pick-up visit was 5% or more of the total days between scheduled appointments or ART pick-up visits.
b 50% drop in CD4þ count from its peak value and return to pre-ART CD4þ count or lower which occurs after 168 days on ART or a viral load greater than 10,000 after 168
days on ART.
c Cumulative incidences are calculated from the date of eligibility for second line eligibility, 168 days after ART initiation.
d Excludes prevalent cases at baseline.
e Excludes pregnant women.
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some of our analyses. After deleting those visits that took place
other than at the site of enrollment or ART initiation, ICCs mostly
decreased, usually by a little, but occasionally by a lot. This is
somewhat surprising since mixing of patients between facilities
should tend to dampen between-facilities variation in outcomerates, making them more alike to one another.
Althoughmany ICCs reported in this paper appear small, sample
size calculations, especially for binary outcomes, are sensitive to
small changes in the ICC. Consider a hypothetical 2-armed cRCT
conducted in Dar es Salaam designed to reduce the 24-month cu-
mulative incidence of immunologic failure from 46% to 36%.
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sample size calculation assuming an ICC of zero would estimate
that a study with 758 patients would achieve 80% power [36].
However, if the true ICC for the study population were 0.0102,
which reﬂects our estimate of the ICC of the 24-month cumulative
incidence of immunologic failure by any deﬁnition and also ap-
proximates the mean of the ICCs reported in this paper, a study
with 50 patients per cluster would require 1200 patients to achieve
80% power, over 1.5 times as many as would have been required in
an individually randomized setting. A study with 100 individuals
per cluster would require 1600 patients to achieve 80% power,
which is over twice as many patients as were required in calcula-
tions that ignored the ICC. These scenarios demonstrate how failing
to account for seemingly small ICCs can result in severely under-
powered studies.
Because sample size calculations are sensitive to small changes
in the ICC, we urge researchers to be cautious when selecting
published ICCs to use in their sample size calculations. As demon-
strated by the variation in point estimates of the ICCs for different
deﬁnitions of immunologic failure, small differences in the deﬁni-
tion of the outcome canmeaningfully change the point estimates of
ICCs. Therefore, we join other authors in recommending that re-
searchers designing RCTs conduct sensitivity analyses to evaluate
their anticipated power under the full range of ICCs suggested by
the conﬁdence intervals [9,37].
This paper calculates the conﬁdence intervals for ICCs using a
formula that is based on a normality assumption. Because binary
outcomes cannot satisfy this normality assumption, the conﬁdence
intervals reported in this paper are not strictly valid for binary
outcomes. This normality assumption also may not be satisﬁed for
all continuous outcomes. Because the calculations of ICC intervals
can be very sensitive to violations of the assumptions of normality,
these conﬁdence intervals should be considered an approximation
of the range of values that could be encountered in practice [38].
Donner and Klar [9] have previously advised against over-
estimating the stability of ICCs calculated from fewer than 40
clusters. Although 47 sites are included in this study, most of our
ICCs were calculated using fewer than 40 sites due to the exclusion
of sites with fewer than 5 events for binary outcomes, 10 mea-
surements for continuous outcomes, or which were extreme out-
liers. The MDH clinics are part of a complex health system, and
some sites serve few patients while others face special circum-
stances causing them to act as outliers. Failing to use exclusion
criteria sometimes resulted in unstable or implausible estimates for
some ICCs. Despite this limitation, the MDH cohort is one of the
largest cohorts of HIV-positive people, and few other cohorts are
better suited to estimating these ICCs. For example, the median
number of sites used in the calculation of our ICCs is greater than
the total number sites available to Zhang et al. [20]. Our ICCs were
calculated among adults attending CTCs in Dar es Salaam, Tanzania.
These ﬁndings will be most useful for researchers randomizing at
the clinic level in urban sub-Saharan African settings, but may also
be useful in other resource-limited settings. Researchers can also
use our estimates to calculate coefﬁcients of variation for binary
outcomes, which have been used in alternative formulas of esti-
mating sample sizes for cRCTs [39]. For binary outcomes, the rela-
tionship between the coefﬁcient of variation and the ICC is
described using the following equation:
ICC ¼ k2
 p
1 p

where k is the coefﬁcient of variation and p is the probability of the
outcome [40]. However, these ICCs cannot be generalized to all
contexts. In particular, ICCs for binary outcomes can only begeneralized to contexts with similar prevalence or cumulative in-
cidences [35].
5. Conclusion
cRCTs provide unique opportunities to evaluate HIV-related in-
terventions, especially for HIV treatment implementation research.
However, researchers can effectively leverage this study design
only if they have access to applicable ICCs needed to accurately
predict the sample size needed to design well-powered, efﬁcient
studies. There is a critical need to provide future researchers with
ICCs for a diverse range of HIV-related clinical outcomes. Despite
some limitations, these estimates provide valuable information,
especially given the current scarcity of ICCs for HIV-related out-
comes. Future researchers conducting cRCTs should consider pub-
lishing ICCs for not only their primary outcomes but also for
secondary outcomes to address this persistent gap in the literature.
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